CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D001523: Mental Disorders NIH

(Synonyms: Mental, Mental, Mental Di, Mental Dis, Mental Disord, Mental Disorde, Mental Disorders)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (16)


Name (Synonyms) Correlation
drug216 Brief Psychiatric Rating Scale Wiki 0.33
drug1502 Zaritt Burden Interview Wiki 0.33
drug1204 SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales Wiki 0.33
drug1068 Pre_lunch pranayama Wiki 0.33
drug974 PSS (Perceived Stress Scale) Wiki 0.33
drug669 Impact of Event Scale-Revised Wiki 0.33
drug499 Exposure to the SARS-CoV-2 and its consequences Wiki 0.33
drug417 Description of groups caracteristics Wiki 0.33
drug496 Exposed to the novel coronavirus disease 2019 Wiki 0.33
drug416 Depression, Anxiety and Stress Scale Wiki 0.33
drug349 Connor-Davidson Resilience Scale 10 items (CD-RISC 10) Wiki 0.33
drug1067 Pre_dinner pranayama Wiki 0.33
drug840 Morning pranayama Wiki 0.33
drug968 PHQ-9 (9-item Patient Health Questionnaire) Wiki 0.33
drug529 GAD-7 (7-item Generalized Anxiety Disorder) Wiki 0.33
drug938 Online Survey Wiki 0.24

Correlated MeSH Terms (6)


Name (Synonyms) Correlation
D000066553 Problem Behavior NIH 0.58
D004194 Disease NIH 0.38
D011618 Psychotic Disorders NIH 0.33
D009461 Neurologic Manifestations NIH 0.19
D045169 Severe Acute Respiratory Syndrome NIH 0.04
D018352 Coronavirus Infections NIH 0.03

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0000708 Behavioral abnormality HPO 0.47

There are 9 clinical trials

Clinical Trials


1 Mental Health and Its Correlates Among Chinese Adolescents Exposed to the Novel Coronavirus Disease 2019: A Longitudinal Study Protocol

Background: Direct exposure to public health emergencies is associated with increased mental disorders. It is less clear about the prevalence of common mental disorders and its correlates in Chinese adolescents after experiencing public health emergencies. Objective: This longitudinal study aims to estimate the prevalence of common mental disorders (i.e. depression, anxiety, and post-traumatic stress disorder) and its correlates in a sample of Chinese adolescents after experience a public health emergency, namely the novel coronavirus disease 2019 (COVID-19). Method: This study intends to recruit 3,428 Chinese adolescent students from high and middle schools in the baseline survey. This study will track these recruited participants every 6 months via three-wave follow-up (i.e. 6-month, 12-month, and 18-month follow-ups). The demographics (e.g. age, gender, education, family background, and residence) and psychosocial factors (i.e. exposure to traumatic events, religious belief, social media exposure, loneliness, and perceived social support) associated with common mental disorders (i.e. depression, anxiety, and post-traumatic stress disorder) will be investigated in this sample population. Furthermore, a hardcopy self-report questionnaire will be disturbed to all participants. Additionally, the cross-sectional analyses will be first conducted to estimate the prevalence of mental disorders and their correlates in data of baseline survey. After obtaining the longitudinal data, the relative risk, incident rate ratios, latent class analysis, and structural equation model may be performed in this study. Missing data will be solved by the multiple imputations. Data analysis tools included the Stata 16.0 and Mplus 8.4. Discussion: This longitudinal study will better help to understand the prevalence changes of mental disorders among Chinese adolescents following the COVID-19. These findings have the potential to provide empirical evidence about the burden of mental disease and key drivers of Chinese adolescents following the COVID-19, which can benefit the formation of public policy and mental health intervention programming. This study will close the gaps that a lack of epidemiological studies about the mental disorder prevalence and related risk factors.

NCT04299711 Mental Disorder Other: Exposed to the novel coronavirus disease 2019
MeSH:Mental Disorders

Primary Outcomes

Description: The prevalence and incidence changes of common mental disorders (i.e. depression, anxiety, and PTSD) in a representative sample of Chinese adolescents

Measure: The prevalence and incidence changes of common mental disorders

Time: 15 Oct 2020 - 15 Nov 2020

Secondary Outcomes

Description: To identify demographics (e.g. age, gender, education, family background, and residence) the major psychosocial factors (i.e. exposure to traumatic events, religious belief, social media exposure, loneliness, and perceived social support) contributing to prevalence and incidence of mental disorders

Measure: Mental disorders and its' correlates

Time: 15 Oct 2020 - 15 Nov 2020

2 The Impact of the Covid-19 Pandemic on the Mental Health of Workers in Health Services: The Covid-19 HEalth caRe wOrkErS (HEROES) Study

Since December 2019 the world has been shaken with an enormous global threat: the Covid-19 pandemic. This new kind of coronavirus is generating an unprecedented impact both on the general population and on the healthcare systems in most countries. Health services are trying to expand their capacity to respond to the pandemic, taking actions such as increasing the number of beds; acquiring necessary equipment to provide intensive therapy (ventilators), and calling retired health professionals and health students so they can assist the overwhelmed health care workforce. Unfortunately, these organizational changes at health facilities, along with the fears and concerns of becoming ill with the virus or infecting their families, put an enormous emotional burden on workers in health services which may lead to negative outcomes on mental health in this population. Recent cross-sectional studies in China indicate that health service workers exposed to people with Covid-19 reported higher rates of depressive and anxious symptoms. This negative impact on mental health among health workers in China has also been informally reported in other countries where the Covid-19 pandemic has been devastating in its effects (such as Spain and Italy), as well as in countries where the pandemic is becoming a growing public health problem. This is particularly relevant in regions with fewer resources (Latin America, North Africa), where there are limited means and the response from the health system is usually insufficient. Moreover, it is necessary to study these negative effects longitudinally considering that some effects will appear over time (post-traumatic stress). Accordingly, this prospective (0, 3, 6 and 12 months), multisite cohort study aims to describe, examine, and evaluate the impact of the Covid-19 pandemic on mental health and social factors among workers at health services from Latin America and the Caribbean, Europe and neighboring countries, the Middle East and North Africa, as well as Sub-Saharan Africa and Asia. Additionally, a team from the United States of America will also participate in this collaborative effort providing expertise on psychiatric epidemiology and supporting coordination across countries.

NCT04352634 Covid-19 Mental Health Disorder Stress Disorder Anxiety Depression SARS-CoV-2 Other: Exposure to the SARS-CoV-2 and its consequences
MeSH:Disease Mental Disorders

Primary Outcomes

Description: The 12-item version of the General Health Questionnaire (GHQ-12) is a self-reported instrument that measures symptoms of anxiety and depression. It provides cut-off points to identify people at risk of anxiety and/or depression, which differ slightly between countries

Measure: Anxiety and depressive symptoms

Time: 12 months

Secondary Outcomes

Description: Ad hoc survey on experiences, fears, and concerns about Covid-19

Measure: Experiences, fears and concerns about the Covid-19

Time: Baseline

Description: Ad hoc survey on experiences, fears, and concerns about Covid-19

Measure: Experiences, fears and concerns about the Covid-19

Time: 3 months

Description: Ad hoc survey on experiences, fears, and concerns about Covid-19

Measure: Experiences, fears and concerns about the Covid-19

Time: 6 months

Description: Ad hoc survey on experiences, fears, and concerns about Covid-19

Measure: Experiences, fears and concerns about the Covid-19

Time: 12 months

Description: Ad hoc survey on Covid-19 training and resource prioritization

Measure: Training and resource prioritization

Time: Baseline

Description: Ad hoc survey on Covid-19 training and resource prioritization

Measure: Training and resource prioritization

Time: 3 months

Description: Ad hoc survey on Covid-19 training and resource prioritization

Measure: Training and resource prioritization

Time: 6 months

Description: Ad hoc survey on Covid-19 training and resource prioritization

Measure: Training and resource prioritization

Time: 12 months

Description: Item from the Columbia Suicide Severity Rating Scale (C-SSRS) that measures suicidal ideation with a dichotomous answer (presence/absence)

Measure: Suicide ideation (presence)

Time: Baseline

Description: Item from the Columbia Suicide Severity Rating Scale (C-SSRS) that measures suicidal ideation with a dichotomous answer (presence/absence)

Measure: Suicide ideation (presence)

Time: 3 months

Description: Item from the Columbia Suicide Severity Rating Scale (C-SSRS) that measures suicidal ideation with a dichotomous answer (presence/absence)

Measure: Suicide ideation (presence)

Time: 6 months

Description: Item from the Columbia Suicide Severity Rating Scale (C-SSRS) that measures suicidal ideation with a dichotomous answer (presence/absence)

Measure: Suicide ideation (presence)

Time: 12 months

Description: 5-point Likert item from the Columbia Suicide Severity Rating Scale (C-SSRS). Higher scores indicate higher frequency.

Measure: Suicide ideation (frequency)

Time: Baseline

Description: 5-point Likert item from the Columbia Suicide Severity Rating Scale (C-SSRS). Higher scores indicate higher frequency.

Measure: Suicide ideation (frequency)

Time: 3 months

Description: 5-point Likert item from the Columbia Suicide Severity Rating Scale (C-SSRS). Higher scores indicate higher frequency.

Measure: Suicide ideation (frequency)

Time: 6 months

Description: 5-point Likert item from the Columbia Suicide Severity Rating Scale (C-SSRS). Higher scores indicate higher frequency.

Measure: Suicide ideation (frequency)

Time: 12 months

Description: Ad hoc 3-item survey to evaluate acute stress disorder. Higher values of the 5-points Likert scales suggest higher frequency of symptoms

Measure: Acute stress symptoms

Time: Baseline

Description: Ad hoc 3-item survey to evaluate acute stress disorder. Higher values of the 5-points Likert scales suggest higher frequency of symptoms

Measure: Acute stress symptoms

Time: 3 months

Description: Ad hoc 3-item survey to evaluate acute stress disorder. Higher values of the 5-points Likert scales suggest higher frequency of symptoms

Measure: Acute stress symptoms

Time: 6 months

Description: Ad hoc 3-item survey to evaluate acute stress disorder. Higher values of the 5-points Likert scales suggest higher frequency of symptoms

Measure: Acute stress symptoms

Time: 12 months

Description: Ad hoc survey on support network. The answers to the multiple items will be adjusted so higher values indicate higher levels of psychological and social support

Measure: Psycho/social support and network

Time: Baseline

Description: Ad hoc survey on support network. The answers to the multiple items will be adjusted so higher values indicate higher levels of psychological and social support

Measure: Psycho/social support and network

Time: 3 months

Description: Ad hoc survey on support network. The answers to the multiple items will be adjusted so higher values indicate higher levels of psychological and social support

Measure: Psycho/social support and network

Time: 6 months

Description: Ad hoc survey on support network. The answers to the multiple items will be adjusted so higher values indicate higher levels of psychological and social support

Measure: Psycho/social support and network

Time: 12 months

Description: The Brief Resilience Scale (BRS) is a 6-item self-reported instrument that measures resilience. The range of scores is 6-30. Higher scores indicate higher resilience levels.

Measure: Resilience

Time: Baseline

Description: The Brief Resilience Scale (BRS) is a 6-item self-reported instrument that measures resilience. The range of scores is 6-30. Higher scores indicate higher resilience levels.

Measure: Resilience

Time: 3 months

Description: The Brief Resilience Scale (BRS) is a 6-item self-reported instrument that measures resilience. The range of scores is 6-30. Higher scores indicate higher resilience levels.

Measure: Resilience

Time: 6 months

Description: The Brief Resilience Scale (BRS) is a 6-item self-reported instrument that measures resilience. The range of scores is 6-30. Higher scores indicate higher resilience levels.

Measure: Resilience

Time: 12 months

Description: The 12-item version of the General Health Questionnaire (GHQ-12) is a self-reported instrument that measures symptoms of anxiety and depression. It provides cut-off points to identify people at risk of anxiety and/or depression, which differ slightly between countries

Measure: Anxiety and depressive symptoms

Time: Baseline

Description: The 12-item version of the General Health Questionnaire (GHQ-12) is a self-reported instrument that measures symptoms of anxiety and depression. It provides cut-off points to identify people at risk of anxiety and/or depression, which differ slightly between countries

Measure: Anxiety and depressive symptoms

Time: 3 months

Description: The 12-item version of the General Health Questionnaire (GHQ-12) is a self-reported instrument that measures symptoms of anxiety and depression. It provides cut-off points to identify people at risk of anxiety and/or depression, which differ slightly between countries

Measure: Anxiety and depressive symptoms

Time: 6 months

3 Impact of Containment and Quarantine During COVID-19 Outbreack on Psychotic Symptoms in the General Population in France

Study the impact of containment related to COVID-19 pandemic on psychotic experiences in the general population in France.

NCT04356885 Mental Disorder
MeSH:Mental Disorders

Primary Outcomes

Description: The CAPS is a 32-item self-report scale designed to measure perceptual anomalies and hallucinatory experience that has already been validated in clinical and nonclinical populations. Each of the 32 items involves a question related to a specific hallucinatory experience to which the participant can answer 'yes' or 'no'. If the participant answers 'yes' they are asked to rate how distressing, how intrusive and how often the experience occurs on separate 1-5 rated Likert scales. The scale total is calculated as the total number items responded to with 'yes' (possible range 0-32) and the subscale totals are calculated as the total of the subscale items (possible range 0-160)

Measure: Total score of the Cardiff Anomalous Perceptions Scale (CAPS)

Time: inclusion, 1 week after inclusion and 1 month after inclusion

Secondary Outcomes

Description: Paranoia Scale : this self-report scale is widely used in the assessment of paranoia in the general population. The scale is comprised of a set of 20 items, answered in a Likert-like scale ranging from 1 (never) to 5 (always). Scores can vary between 20 and 100, where higher scores indicate greater paranoid ideation

Measure: Paranoia Scale

Time: inclusion, 1 week after inclusion and 1 month after inclusion

4 A Study of Perceived Distress and Psychological Burden in Patients Suffering From Severe Mental Diseases During the COVID-19 Pandemic in Italy

Despite being originated in Wuhan, in the China mainland region of the Hubei, Italy has been the hardest-hit country in the world by the COVID-19 pandemic during the month of March. Due to the uncontrollable spread of the contagion, the Italian Government has been forced to impose a series of restrictions and social distancing measures, culminating in the extension of lockdown to the entire Italian territory on March 8th. During this period, the general population has been overwhelmed by feelings of worry, anxiety, and discomfort. The discomfort is reinforced by the lengthening of the lockdown, to the point that it may be considered as a mass model of chronic or subchronic mild stress. The predictable effects of this stress on mental health have already been claimed, Post-traumatic symptoms were found in 7% among 285 Wuhan and surrounding cities' residents during the COVID-19 outbreak. A recent survey in the Italian general population reported similar outcomes. In this context, the psychic conditions of the most fragile ones, i.e. those already affected by a severe mental disorder, represent a major concern. Having a history of psychiatric illness is regarded as one of the most relevant predictors of a negative psychological impact of quarantine. Patients with severe mental disorders may be among the hardest hit subjects, as they may be more vulnerable by the COVID-19 outbreak for a series of clinical and psychological factors. In the Italian context, the vulnerability of these patients may be increased by the lockdown of mental health services as a consequence of mass quarantine and optimization of health resources toward action to contrast COVID-19-related sanitary emergencies. Despite several reports investigated the psychological effects of COVID-19 pandemic on health-care workers, COVID-19 affected people, or the general population, at the moment, no study has investigated the effects of the distress caused by fear of contagion and mass quarantine on severe mental disorder patients. The present study aimed at providing a first evaluation of anxiety, depressive, stress-related symptoms in these patients.

NCT04357769 Psychological Distress COVID Severe Mental Disorder Other: PSS (Perceived Stress Scale) Other: GAD-7 (7-item Generalized Anxiety Disorder) Other: PHQ-9 (9-item Patient Health Questionnaire) Other: SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales Other: Zaritt Burden Interview
MeSH:Mental Disorders

Primary Outcomes

Description: Significant differences among groups in the mean Perceived Stress Scale (PSS) score, which measures the stress severity perceived by the subjects in the last month. The scale is constituted by 10 items that are self-rated by the subject on a 0-4 Likert scale. The scale minimum total score is 0, the maximum is 40. Higher total scores indicate a worse outcome

Measure: Perceived Stress Scale (PSS) outcome

Time: 10 days

Secondary Outcomes

Description: Significant differences among groups in the mean Generalized Anxiety Disorder (GAD-7) scale score, which measures anxiety symptoms' severity in the last two weeks. The scale is constituted by 7 items that are self-rated by the subject on a 0-3 Likert scale. The scale minimum total score is 0, the maximum is 21. Higher total scores indicate a worse outcome

Measure: Generalized Anxiety Disorder (GAD-7) scale outcome

Time: 10 days

Description: Significant differences among groups in the mean Patient Health Questionnaire (PHQ-9) scale score, which measures depressive symptoms' severity in the last two weeks. The scale is constituted by 9 items that are self-rated by the subject on a 0-3 Likert scale. The scale minimum total score is 0, the maximum is 21. Higher total scores indicate a worse outcome

Measure: Patient Health Questionnaire (PHQ-9) scale outcome

Time: 10 days

Description: Significant differences among groups in the mean Specific Psychotic Experiences Questionnaire (SPEQ) - Paranoia subscale score. The SPEQ scale is designed for the assessment of current sub-threshold psychotic symptoms in multiple domains. The Paranoia subscale measures persecutory/reference ideas and is constituted by 15 items that are self-rated by the subject on a 0-5 Likert scale. The subscale minimum total score is 0, the maximum is 75. Higher total scores indicate a worse outcome

Measure: Specific Psychotic Experiences Questionnaire (SPEQ) - Paranoia subscale outcome

Time: 10 days

Description: Significant differences among groups in the mean Specific Psychotic Experiences Questionnaire (SPEQ) - Grandiosity subscale score. The Grandiosity subscale measures grandiosity/megalomaniac ideas and is constituted by 8 items that are self-rated by the subject on a 0-3 Likert scale. The subscale minimum total score is 0, the maximum is 24. Higher total scores indicate a worse outcome

Measure: Specific Psychotic Experiences Questionnaire (SPEQ) - Grandiosity subscale outcome

Time: 10 days

Description: Significant correlations between mean Zarit Burden Interview (ZBI) and mean scores on the Perceived Stress Scale (PSS). The ZBI is designed for the assessment of caregiver burden. The scale is constituted by 22 items that are self-rated by the subject on a 0-4 Likert scale. The scale minimum total score is 0, the maximum is 88. Higher total scores indicate a worse outcome

Measure: Caregiver Burden

Time: 10 days

5 PSYCHIatric Disorders and Covid-19 (PSYCHIC) : Observatory of the Psychiatric, Somatic and Pharmacological Impacts of the COVID-19 Pandemic on Patients Hospitalized for Psychiatric Disorders and Suspected to be Infected by COVID-19

Given the possible risks and complications of a comorbidity between psychiatric disorder and coronavirus disease 2019 (COVID-19), it seems particularly important to specify the impact of the COVID-19 pandemic in patients with psychiatric disorders and suspected of infection, hospitalized in a specific unit, at the psychiatric, somatic and pharmacological level.

NCT04358042 Psychiatric Disorder Covid19 Other: Brief Psychiatric Rating Scale Other: Depression, Anxiety and Stress Scale Other: Impact of Event Scale-Revised Other: Connor-Davidson Resilience Scale 10 items (CD-RISC 10)
MeSH:Disease Mental Disorders Problem Behavior
HPO:Behavioral abnormality

Primary Outcomes

Description: total severity score from the Impact of Event Scale-Revised (IES-R)

Measure: impact of the COVID-19 pandemic on psychiatric symptomatology

Time: through study completion, an average of 2 year

6 Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders: An Observational Study of the Covid-19 Neurological and Psychiatric Manifestations

Covid-19 pandemic now affects more than two million people worldwide. The neurotropism of the virus is assumed by its frequent association with neurological symptoms (anosmia, ageusia, headaches) but the extent of the central or peripheral nervous system involvement and the associated symptomatology remain poorly known for now. The main objective of this study is to describe the neurological and psychiatric manifestations occurring in the context of Covid-19 infection in patients hospitalized or followed-up in the APHP.SU hospital group. A better understanding of the neuropsychiatric impairment related to Covid-19 would improve the management of these patients in the acute phase, and knowledge of subsequent complications would allow adapting their rehabilitation and follow-up. The precise phenomenological description of these manifestations and the imaging, biology and neuropathology data will be compiled from the data collected by the physicians in charge of these patients as part of their inpatient or outpatient care. This study will also allow collecting unusual clinical manifestations from patients followed for neurological or psychiatric pathology in hospital departments and presenting a Covid-19 infection, in order to optimize the reorganization of their management, follow-up and rehabilitation in the epidemic context.

NCT04362930 Neurologic Manifestations Psychiatric Disorders COVID-19
MeSH:Neurologic Manifestations Disease Mental Disorders Problem Behavior
HPO:Behavioral abnormality

Primary Outcomes

Description: Frequency of central or peripheral neurological or psychiatric symptoms observed in patients with COVID-19

Measure: Central or peripheral neurological symptoms or psychiatric symptoms observed in patients with Covid-19

Time: 12 months

Secondary Outcomes

Description: Impact on neurological or psychiatric disease trajectories assessed by severity scores or subjective progression (improved, stable, impaired) during and after COVID-19 pathology in patients with pre-existing neurological and psychiatric diseases

Measure: Progression of pre-existing neurological or psychiatric pathologies

Time: 12 months

7 Psychological Impact and Effect of the Corona Virus (SARS-CoV-2) Pandemic in Individuals With Psychiatric Disorders - an Online Survey

The aim of this study is to measure current affective symptoms and psychological distress in individuals with severe mental illness during the COVID-19 pandemic using an online questionnaire survey. In addition, this study aims at identifying individual beliefs, sleep quality, attitudes concerning the virus, the adherence to the measures, believing processes, and coping strategies/resilience patterns referring to COVID-19 in different study centers.

NCT04410835 Corona Virus Infection Psychiatric Disorder Psychological Distress Diagnostic Test: Online Survey
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Mental Disorders Problem Behavior
HPO:Behavioral abnormality

Primary Outcomes

Description: Brief Symptom Inventory-18

Measure: Global symptom load (Anxiety, Somatisation, Depression, Global Symptom Index)

Time: 1 year

Description: Beck Depression Inventory-II

Measure: Depressive symptoms

Time: 1 year

Description: Pittsburgh Sleep Quality Index

Measure: Sleep disorders and Sleep Quality

Time: 1 year

Secondary Outcomes

Description: COVID-19 questionnaire including questions about physical activity, eating behavior, substance use, smoking

Measure: Life style changes

Time: 1 year

Description: Food Craving Inventory

Measure: Food Craving

Time: 1 year

Description: COVID-19 questionnaire

Measure: COVID-19 associated fears and emotional responses to the pandemic

Time: 1 year

8 Yoga- Based Breathing for Vagus Nerve Stimolation as Home-care Adjuvant Treatment Against Burden COVID 19 Outbreak

COVID-19 mortality occurs mainly from immunological behavior or by suicide after healing . In both cases, the causal link is coronavirus within the host response. The rationale of use of deep yoga breathing as adjuvant treatment to COVID-19 disease , is linked to the mechanical action to stimulate the vagus nerve through scalene and sternocleidomastoid muscles function of which the continuity of action bring to modulate upto suppress, the inflammatory reflex and pro-inflammatory cytokines overproduction and contestual slowering of the sympathetic stress response as a first cause of sleep and late mental disorders which can increase the annual suicide rate. An easily breathing medical Yoga protocol has been developed to test a cost-effective care provision, training, contact tracing and mass efficacy testing.

NCT04413747 Coronavirus Infection Cytokine Storm Mental Disorder Behavioral: Morning pranayama Behavioral: Pre_lunch pranayama Behavioral: Pre_dinner pranayama
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Mental Disorders Psychotic Disorders
HPO:Psychosis

Primary Outcomes

Description: COVID 19's Patients mortality all cause incidence proportion

Measure: Mortality

Time: 12 months

Description: COVID 19's Patients suicide rate

Measure: Mortality-suicide

Time: 12 months

Secondary Outcomes

Description: In-hospital COVID19's Patients oxygen use, invasive ventilation or high flow oxygen devices incidence proportion

Measure: Need of hospitalization for respiratory failure of COVID19's Patients

Time: 12 months

Description: At home or telematic incidence proportion of professional psychiatric-psychological interventions for anxiety and depression

Measure: Homecare professional psychiatric-psychological interventions for COVID19's Patients

Time: 12 months

Description: Rate of positive scores for depression and anxiety according to the Pittsburgh Sleep Quality Index (PSQI) requiring drug treatment

Measure: Sleep disturbances of COVID 19's Patients as mental disorder

Time: 12 months

9 Caracteristics of the Patients Hospitalized With Unvonluntary Commitment Procedure, in Pandemic and Confinement Context

The actual worldwide context (disease outbreak, confinements instaured in many countries) is a stressful factor for many people. It can have consequences on mental health : separation from loved ones, loss of freedom, uncertainty about infection status, boredom. Patients with mental disorders are especially vulnerable. On march 17th, the french government ordonned a national confinement to slow the progression of the COVID-19 outbreak, for 15 days at first then renewed several times. This situation has led to a reorganization of care as requested on March 22nd, 2020 in the recommendations applicable to the organization of care in psychiatric services : priority to telephone contacts and teleconsultation by multiplying contacts and assessments. By the time the reorganization of care became operational, the most vulnerable patients may have experienced a decompensation of their disease. It is important to know if the COVID-19 outbreak combined with the confinement increased the number of unvoluntary commitment the month after the announce of the confinement. This could help us understand which patients are more vulnerable is this context, and improve our organization (ambulatory and hospitalization care) if this situation occurs again.

NCT04417374 COVID 19 Disease Outbreak Mental Disorders Other: Description of groups caracteristics
MeSH:Mental Disorders

Primary Outcomes

Description: Number of hospitalized patients From March 12th to April 09th

Measure: Number of hospitalized patients

Time: 1 months

Secondary Outcomes

Description: Primary psychiatric diagnostic From March 12th to April 09th

Measure: Cause of hospitalization

Time: 1 months

Other Outcomes

Description: Patients without psychiatric antecedent (number) From March 12th to April 09th

Measure: Lengh of hospitalization

Time: 1 months

Description: Presence of absence of history of treatment interruption leading to the hospitalization From March 12th to April 09th

Measure: Treatment interruption

Time: 1 months

Description: Number of hospitalized patients living alone (opposed to those living with family) From March 12th to April 09th

Measure: Number of hospitalized patients living alone

Time: 1 months

Description: Number of patients using drugs From March 12th to April 09th

Measure: Use of drugs

Time: 1 months


HPO Nodes